Skip to main content
. 2018 Jan;59(1):462–471. doi: 10.1167/iovs.17-23159

Figure 2.

Figure 2

Sarpogrelate treatment results in transient MAPK/ERK activation. Line graphs showing average fold change in phosphorylation of key proteins in the MAPK/ERK pathway at multiple times post injection (A) and post light exposure (B). Data points are presented as mean ± standard error. A 2-way ANOVA multiple comparisons test was used to compare fold changes between Sarp+No LE and Saline+No LE groups in (A) and also used to compare fold change difference between Sarp+LE and Saline+LE in (B). *P ≤ 0.05. n = 3 to 5 animals per group. Sarp, 25 mg/kg sarpogrelate; p, phosphorylated; PKC, protein kinase C; MEK, mitogen-activated protein kinase kinase; ERK1/2, extracellular signal–related kinase 1/2.